​With continuing strong investor interest in cell therapies and rare diseases, are they all attractive for biotechs and venture capital?  What factors are executives and investors looking for in new opportunities?   Please join a panel of industry veterans for a discussion and Q&A “Inside the Veil” of cell and rare disease therapies and business development evaluations.

Key Discussion Questions​:

• What key business questions will investors consider for cell and rare disease opportunities?
• Does the stage of an opportunity matter in terms of how investors will weigh scientific and operational questions against the overall business and commercial opportunities?
• How can startups and entrepreneurs best articulate their value proposition to raise money and attract potential partners?

​Panelists:

• ​Rich Brodsky, Principal, Head of Strategy, Naveos Biopharma Consulting
• ​Amanda Hayward, Global Head of Business Development, Rallybio
• ​Han Lee, President, CFO, ImmPACT Bio
• ​Moderator: Manuel Mohr, Blavatnik Fellow, Yale Ventures